PRMT1 and neoplasm: In addition, the PRMT1 knockdown group (tumor weight of 0.2 mg) showed markedly inhibited in vivo tumor growth of U87MG GSCs compared with the negative control group (tumor weight of 3.7 mg) in the CAM model (Figure 5C).